While our study is limited by the ethical constraints in the collection of biopsy samples from patients with resolved psoriasis, our findings suggest that epidermal CD49a+ Trm cells may be useful as prognostic markers of disease severity or treatment efficacy. This evidence concerns the gene ITGA1 and psoriasis.